# Averna Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/averna-therapeutics

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.exsiliotx.com
- Total disclosed funding: $39M
- Latest round: Series A (Apr 8, 2024)
- Investors on record: 10

## About

Founded in 2022 and based in New York, US, Exsilio Therapeutics Inc. operates as a biotechnology company that develops genomic medicines for the treatment of various autoimmune and genetic diseases. In June 2024, Exsilio Therapeutics Inc. raised USD 82 million in Series A funding co-led by Novartis Venture Fund and Delos Capital Partners, with participation from OrbiMed Advisors, Insight Partners, J.P. Morgan Alternative Asset Management, CRISPR Therapeutics AG, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight.

The firm develops and offers genomic medicines using lipid nanoparticles to address a wide range of diseases, including genetic disorders, cancer, and autoimmune conditions. Their technology leverages naturally occurring genetic elements to insert new genes into cells via RNA intermediate templates. This process is enhanced through predictive in silico modeling and laboratory experimentation. The medicines are encoded in mRNA, enabling delivery through non-viral platforms that are safe, efficient, scalable, and allow for redosing. Exsilio aims to provide curative treatments by inserting therapeutic genes into safe harbor sites within DNA.

The company intends to use the June 2024 funding to support its expansion and development.

## Funding rounds

- Series A, Apr 8, 2024, $39M — OrbiMed Advisors, Insight Partners, Novartis Venture Fund, Invus [DUP], J.P. Morgan Alternative Asset Management, Innovation Endeavors, CRISPR Therapeutics AG, Delos Capital Partners, Arc Ventures, Deep Insight

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Invus [DUP] — Series A
- J.P. Morgan Alternative Asset Management — Series A
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series A
- CRISPR Therapeutics AG — Series A
- Delos Capital Partners (https://capitalatlas.ai/funds/delos-capital-partners) — Series A
- Arc Ventures — Series A
- Deep Insight (https://capitalatlas.ai/funds/deep-insight) — Series A